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Phenocopy frontotemporal dementia (phFTD) shares core characteristics with behavioral
variant frontotemporal dementia (bvFTD), yet without associated cognitive deficits and
brain abnormalities on conventional magnetic resonance imaging (MRI), and without
progression. Using advanced MRI techniques, we previously observed subtle structural
and functional brain changes in phFTD similar to bvFTD. The aim of the current
study was to follow these as well as cognition in phFTD over time, by means of
a descriptive case series. Cognition, gray matter (GM) volume and white matter
(WM) microstructure, and perfusion of 6 phFTD patients were qualitatively compared
longitudinally (3-years follow-up), and cross-sectionally with baseline data from 9 bvFTD
patients and 17 controls. For functional brain changes, arterial spin labeling (ASL)
was performed to assess GM perfusion. For structural brain changes, diffusion tensor
imaging was performed to assess WM microstructure and T1w imaging to assess GM
volume. MRI acquisition was performed at 3T (General Electric, US). Clinical profiles of
phFTD cases at follow-up are described. At follow-up phFTD patients showed clinical
symptomatology similar to bvFTD, but had a relatively stable clinical profile. Longitudinal
qualitative comparisons in phFTD showed some deterioration of language and memory
function, a stable pattern of structural brain abnormalities and increased perfusion
over time. Additionally, both baseline and follow-up cognitive scores and structural
values in phFTD were generally in between those of controls and bvFTD. Although a
descriptive case series does not allow for strong conclusions, these observations in a
unique longitudinal phFTD patient cohort are suggestive of the notion that phFTD and
bvFTD may belong to the same disease spectrum. They may also provide a basis for
further longitudinal studies in phFTD, specifically exploring the structural vs. functional
brain changes. Such studies are essential for improved insight, accurate diagnosis, and
appropriate treatment of phFTD.
Keywords: frontotemporal dementia, diffusion tensor imaging, white matter, cognition, perfusion, gray matter,
magnetic resonance imaging, cerebral blood flow
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INTRODUCTION
Phenocopy frontotemporal dementia (phFTD) is a clinical
syndrome predominantly affecting men (1), that is much
debated, as it shares core features with behavioral variant
frontotemporal dementia (bvFTD) but does not follow its
disease course. These core features are behavioral changes,
such as apathy, behavioral disinhibition, and loss of insight
(2). However, phFTD patients do not show the cognitive and
brain abnormalities that are typical for bvFTD. The cognitive
profile of phFTD patients may range from normal to suggesting
bvFTD (3–6) but it appears stable over time, whereas in bvFTD
rapid progression of cognitive deficits is evident (6–9). On
conventional (structural) magnetic resonance imaging (MRI),
phFTD patients show no or only mild abnormalities (7, 9) in
the frontotemporal brain regions typically affected in bvFTD
(10). Consequently, as a pathophysiological explanation is not
yet available, diagnosis in phFTD is complicated. Patients often
remain undiagnosed or may receive an uncertain psychiatric
diagnosis, as PhFTD symptoms may be similar to those
of psychiatric disorders, such as decompensated pre-existing
personality disorders, late onset bipolar disorder and late-onset
atypical psychosis (11–13). The issue of whether phFTD is a
psychiatric or neurodegenerative disease could possibly be settled
by observing brain abnormalities similar to bvFTD that progress
over time, which have not been previously found in phFTD.
In our previous work (14, 15) we aimed to address this
diagnostic concern and lack of neurological explanation by using
advanced MRI techniques to investigate the possible presence of
subtle brain abnormalities. Using diffusion tensor imaging (DTI)
we observed white matter (WM) microstructure abnormalities
in the frontal and temporoparietal lobes in phFTD similar to,
but less pronounced than in bvFTD (14). Using an advanced
post-processing method of structural imaging to explore gray
matter (GM) volumes, we observed loss of GM volume in the
right temporal lobe compared with healthy participants (15).
Additionally, we observed a continuum of regional—especially
frontotemporal—GM volumes ranging from normal in healthy
participants to abnormal in bvFTD, with phFTD in between,
with volumes not significantly different from neither normal nor
bvFTD (15). Using resting state functional MRI (rs-fMRI) we
observed increased functional connectivity in phFTD compared
with healthy participants, in nearly all regions of the default mode
network (DMN). This was similar to but more pronounced than
in bvFTD (14). Using arterial spin labeling (ASL) we observed
left frontal hyperperfusion in comparison with bvFTD and
healthy participants (15). These findings suggest that subtle brain
abnormalities are present in phFTD. Furthermore, psychiatric
assessment ruled out a psychiatric diagnosis for this sample. As
these abnormalities are similar to bvFTD—in addition to their
similar symptomatology and lack of psychiatric diagnosis—we
suggested that phFTD and bvFTDmay belong to the same disease
spectrum. To our knowledge, these subtle brain abnormalities
as detected by advanced neuroimaging techniques have not
been studied in phFTD elsewhere, and neither have they been
longitudinally assessed. In order to gain more insight into
possible longitudinal brain changes in phFTD and to acquire
more support for the notion that phFTD and bvFTD may
belong to the same disease spectrum, we present clinical reports
and qualitatively describe findings from advanced MRI and
neuropsychological examination of six phFTD patients at 3-
years follow-up. We hypothesized that the more subtle brain
abnormalities and cognitive impairment in phFTD at follow-up
would show a slight deterioration in comparison with baseline,
yet not fulfilling bvFTD criteria and still being in-between bvFTD
and healthy participants.
METHODS
Participants
All patients were recruited in the Alzheimer Center Rotterdam.
We included phFTD patients (aged 40–75 years) with prominent
behavioral changes interfering with social functioning, that
were similar to bvFTD symptomatology (e.g., disinhibition,
apathy, stereotypy); and without reported progression on
neuropsychological and neurological assessment and MRI 1 year
after initial routine diagnostic workup. From a larger study
in our center, we included patients (aged 45–70 years) with
a diagnosis of early-stage bvFTD (16)—based on neurological,
neuropsychological and radiological assessment—and a Mini-
Mental State Examination (17) (MMSE) score of ≥20. These
patients meet the criteria for probable bvFTD. Patients with
other neurological disorders, past or current substance abuse or
other psychiatric diagnosis were excluded. Additionally, phFTD
patients with a diagnosis of dementia ormissing heteroanamnesis
were also excluded.
Healthy controls (aged 60–70 years), without neurological or
psychiatric history, were recruited through advertisement. They
were matched for gender with phFTD patients and for age with
all patients.
The study was approved by the local medical ethics
committee. All participants gave written informed consent for
participation in the study and publication of the case studies.
Participant Assessment
PhFTD patients received an MRI scan, neuropsychological
examination, MMSE, psychiatric assessment and genetic testing
of the C9ORF72 repeat expansion at baseline. Psychiatric
assessment was performed to rule out major psychiatric disorders
other than dementia that could explain the current behavioral
changes present in phFTD, specifically focusing on late-onset
psychotic disorders, manic episodes, major depression disorder,
anxiety disorders and autism spectrum disorder. The assessment
was conducted by a qualified psychiatrist and consisted of an
interview with the patient and their caregiver, during which the
Brief Psychiatric Rating Scale [BPRS (18); Dutch translation (19)]
was administered. Genetic testing was performed because FTD
with the C9ORF72 repeat expansion may occasionally mimic
phFTD, with cognitive deficits remaining stable over years (20).
Such cases would have to be excluded from our phFTD sample.
For convenience we will refer to the above described group
as “baseline phFTD.” At 3-years follow-up, phFTD patients
received an MRI scan, neuropsychological examination and
MMSE. BvFTD patients and controls underwent an MRI scan,
neuropsychological examination and MMSE only once.
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Image Acquisition and Assessment
Scanning was performed on two 3T GE Discovery MR750
systems (GE Healthcare, Milwaukee, WI, US) with identical
protocols. PhFTD patients (both at baseline and follow-up) and
9 controls (baseline) were scanned on one, and bvFTD patients
and 8 controls (baseline) on the other scanner.
For clinical radiological assessment by a neuroradiologist and
GM structural assessment, a high-resolution 3-dimensional (3D)
inversion recovery (IR) fast spoiled gradient-echo (FSPGR) T1-
weighted scan was acquired [duration 4.41min; field of view
(FOV) 240mm; inversion time (TI) 450ms; echo time (TE)
3.06ms; repetition time (TR) 7,904ms; acquisition matrix 240 ×
240 mm2; slice thickness 1mm; isotropic voxel size 1 mm3; 176
slices; array spatial sensitivity encoding technique acceleration
(ASSET) factor 2, flip angle 12◦].
For cerebral blood flow (CBF) measurements, ASL scans
were acquired using whole-brain 3D pseudo-continuous ASL
(p-CASL), which is currently the recommended sequence for
clinical use (21) (duration 4.29min; FOV 240mm; TE 10.5ms;
TR 4,632ms; isotropic voxel size 3.3 mm3; 36 axial slices;
interleaved fast spin-echo stack-of-spiral readout 512 sampling
points on eight spirals; background suppression; labeling
duration 1,450ms; number of excitations 3; post-labeling delay
1,525; labeling plane 9 cm below anterior commissure–posterior
commissure line).
For WM microstructure diffusion measurements, DTI scans
with full coverage of the supratentorial brain were acquired
using a spin echo echo planar imaging (EPI) sequence (duration
3.50min; FOV 240mm; TE set to minimum with mean 84.04ms
(range: 81.9–90.8ms; TE mean and range based on baseline
scans); TR 7,925ms; acquisition matrix 128 × 128mm, slice
thickness 2.5mm; voxel size 1.88 × 1.88 × 2.5 mm3; 28 volumes
with 59 axial slices each; 3 non-diffusion weighted volumes; 25
diffusion-weighted directions; maximum b-value 1,000 s/mm2;
ASSET factor 2; flip angle 90◦).
GM volumes and CBF were post-processed according to the
methods previously described in Bron et al. (22) and applied
in Steketee et al. (15) and Meijboom et al. (14). In brief, SPM8
was used for segmentation of GM, WM and CSF tissue maps,
which were then transformed to ASL image space using Elastix
registration software (23) for partial volume correction. Partial
volume corrected ASL images were quantified using the single-
compartment model (21). A multi-atlas approach was used to
establish whole-brain and regional GM volumes expressed as
percentage of intracranial volume (%ICV), and whole-brain and
regional mean CBF (in ml/100 g gm/min). Appropriate regional
CBF values were averaged to establish mean CBF for each
brain lobe.
WM diffusion was post-processed using tractography
according to the methods previously applied in Steketee et al.
(24). In brief, automated probabilistic tractography [AutoPtx
(25)] was performed to apply DTIFit (26) for fitting the
tensor, and to apply BEDPOSTX and PROBTRACKX (26, 27)
for creating WM tract images. Median fractional anisotropy
(FA) was then established for bilateral WM tracts: anterior
thalamic radiation, cingulate and hippocampal cingulum,
inferior fronto-occipital fasciculus, inferior and superior
longitudinal fasciculus, uncinate fasciculus, and forceps
minor and major.
Neuropsychological Data Acquisition and
Assessment
Cognitive testing was performed and evaluated by a
neuropsychologist at Alzheimer Center Rotterdam. These
cognitive tests and associated cognitive domains used for
qualitative assessment are listed in Table 1. The patients and
controls described here were recruited as part of two different
studies, with each study administering different additional
cognitive tests. The scores for these additional tests are not
reported (Table 1).
Test scores were transformed to z-scores using the mean
and standard deviation of controls as a reference. For domains
assessed with more than one test (Table 1), z-scores were
averaged to establish one score per domain (SPSS21.0, New
York, USA).
Qualitative Analysis of Baseline vs.
Follow-Up Measures
Seven phFTD patients were included for baseline. Upon follow-
up, one phFTD patient was excluded due to lack of follow-up
data: the family of the patient did not want him to participate. Six
phFTD patients underwent follow-up assessment, one of whom
did not undergoMRI due to a pacemaker placed after the baseline
visit. Only neuropsychological examination was performed in
this patient.
TABLE 1 | Cognitive domains and their specific neuropsychological tests used to
assess cognitive functioning in patients and controls.
Cognitive
domain
Neuropsychological test Included in
cognitive
domains for
qualitative
comparison
Attention and
executive
functions
Trail Making Test (TMT) (28) X
Stroop color-word task (29) X
Categorical and letter fluency test (30) X
Modified Wisconsin Card Sorting test (WCST)
(31)
X
Letter Digit Substitution Test (LDST) (32) X
Language Boston Naming Test (60 items) (33) X
Memory 15 Words Test (34) X
Digit Span of the Wechsler Adult Intelligence
Scale third edition (WAIS-III) (35)
×
Mini-Mental State Examination (MMSE)
orientation questions (17)
X
Visual Association Test (36) ×
Visuoconstructive
functioning
Clock drawing (37) X
Social cognition Ekman Faces (38) ×
The third column specifies which tests were available for all participants and thus included
in the qualitative comparison of cognitive domains across participants.
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Data and results from reference groups (phFTD at baseline,
cross-sectional bvFTD and control data) previously described
(14, 15) were used for qualitative comparison with phFTD
patients at follow-up. The phFTD patient that was excluded from
follow-up was for that reason also excluded from the baseline
group. Three bvFTD patients were excluded due to incomplete
data: two had missing neuropsychological data and one had ASL
scans of unusable quality.
In total, cognitive, DTI, ASL, and structural imaging data of
6 phFTD patients at baseline and follow-up (5 for MRI data),
9 bvFTD patients and 17 controls were used for qualitative
comparisons (i.e., no statistical tests were used). For each group,
we reported mean and range of cognitive domain z-scores, WM
tract FA, whole-brain GM volume (%ICV) and whole-brain and
regional CBF per group (SPSS21, New York, USA). To gain
insight on a case level, we additionally reported baseline and
follow-up measurements for these variables for each case. Cases
with a 10% difference between both time points were highlighted
to separate these from cases with only minimal differences.
Demographics of Previously Described
Reference Groups (14, 15)
Age did not differ between phFTD at baseline, bvFTD and
controls [F(2) = 0,856 p > 0.05; Welch-ANOVA test]. The
ANOVA test for MMSE score was significant [F(2) = 4.035,
p = 0.028], and post-hoc between-group comparisons showed
a lower MMSE score in phFTD than in controls (p = 0.041)
(SPSS21.0, New York, USA). See Table 2 for an overview of
the demographics.
None of the phFTD patients received an alternative
psychiatric diagnosis at baseline that could explain their
behavioral symptoms. Additionally, none carried the C9ORF72
repeat expansion.
RESULTS
Follow-up neuropsychological assessment was performed
with a mean of 2.93 years (range 2.67–3.08) after baseline
neuropsychological assessment. For MRI at follow-up this was
2.98 (range 2.79–3.15).
TABLE 2 | Demographic characteristics of baseline reference groups used.
Group N Mean age Mean MMSE Education level
PhFTD 6 (6 male) 63.8 (59-70) 26.3 (24-28) 4.5 (4-6)
BvFTD 9 (4 male) 60.1 (43-69) 27.1 (24-30) 4.6 (3-6)
Controls 17 (17 male) 64.1 (56-69) 28.3 (25-30) 5.5 (4-7)
phFTD, phenocopy frontotemporal dementia; bvFTD, behavioral variant frontotemporal
dementia; N, sample size. Values given as mean (range). MMSE, Mini-Mental State
Examination. Education levels reported using the Dutch Verhage education scale (1964):
with 1 = <6 years of primary education, 2 = completed primary education, 3 = primary
education and <2 years of secondary education, 4 = completed low-level secondary
education, 5 = completed middle-level secondary education, 6 = completed high-level
secondary education, 7 = university education (39, 40).
Case Descriptions
All cases showed a clinical profile suggestive of bvFTD.
Increased behavioral changes were reported by the patient
or partner in 5 out of 6 patients; for one patient this
information was not available. Neuropsychological reports
stated that some progression of cognitive abnormalities
was present in five patients in comparison with baseline,
but evident progression was lacking. One patient showed
a normal cognitive profile similar to his baseline profile.
Radiological reports showed no progression of brain
abnormalities in 4 out of 5 patients, and varied from
normal to global abnormalities unspecific for bvFTD. In
one patient, a mild progression of global abnormalities was
reported. A summary of MRI abnormalities can be found
in Table 3.
Case 1
Patient 1 was a 64-years-old male in whom behavioral changes
were first noticed 15 years previously. Major complaints
involved loss of empathy, increased and uncontrolled anger,
loss of initiative, compulsivity, irritability, increased talking and
moving. At follow-up, increased anger and irritability, and
decreased empathy were reported by the partner.
The neuropsychological report at follow-up stated disorders
of language (naming), divided attention and social cognition.
Additionally, mild abnormalities in the executive functions
and working memory/memory were observed. In comparison
with the neuropsychological report at baseline the patient
showed a very mild progression of language, memory and
divided attention abnormalities. Although the clinical and
neuropsychological profile suggested bvFTD, the protracted
disease course and lack of evident progression of cognitive
dysfunctioning did not support the clinical diagnosis of
probable bvFTD.
The radiological report at follow-up stated that no
GM atrophy or WM abnormalities were observed on
conventional MRI.
Case 2
Patient 2 was a 73-years-old male in whom behavioral changes
were first noticed at least 12 years previously. Major complaints
included increased dependency on his partner, loss of initiative,
apathy, increase of food intake, and the inability to cope with
changes. At follow-up, a general worsening of complaints was
reported by the partner, with which the patient disagreed.
The neuropsychological report at follow-up stated disorders of
naming, task-switching, visuo-associative memory and emotion
recognition. In comparison with baseline neuropsychological
examination there was a decrease in memory functioning and
inhibition. The other cognitive functions were of similar level
to baseline.
The radiological report of conventional imaging at follow-
up stated a mild increase of global GM atrophy [global
cortical atrophy scale 1 (GCA)], and no regional GM atrophy.
Additionally, it stated the presence of previously described WM
lesions (Fazekas 3), which were most likely of vascular origin.
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TABLE 3 | Summary of follow-up radiological assessment for each phFTD case.
Case 1 Case 2 Case 3 Case 4* Case 5 Case 6
Changes (T1–T0) No Yes No – No Yes
Gray matter atrophy None GCA 1 >> GCA 1 GCA 1 None Minimal frontal atrophy
White matter changes None Fazekas 3 None Fazekas 1 None None
Infarct None None None None Cortical, lacunar None
Microbleeds None None None None None 3>>
*Baseline scan, follow-up was unavailable due to pacemaker.
>> Indicates an increase in comparison with baseline.
T1, follow-up; T0, baseline; phFTD, phenocopy frontotemporal dementia; GCA, global cortical atrophy.
Case 3
Patient 3 was a 74-years-old male in whom behavioral changes
were first noticed at least 8 years previously. Major complaints
included angry and aggressive behavior, impulsivity, decreased
empathy, sexual disinhibition, speech disinhibition, compulsive
information gathering, and no symptom insight. At follow-up,
no change in complaints was observed.
The neuropsychological report at follow-up stated weak scores
on verbal memory and emotion recognition. Other domains
showed average or just-below average scores. In comparison with
baseline neuropsychological examination, emotion recognition
was more abnormal, but in contrast, scores for a complex
executive task were higher. Scores on the other domains showed
no changes.
The radiological report of conventional imaging at follow-up
stated no regional, but very mild global atrophy (GCA 1). No
changes were observed in comparison with baseline MRI.
Case 4
Patient 4 was a 62-years-old male in whom behavioral changes
were first noticed at least 10 years previously. Major complaints
included severe forgetfulness, letter switching during speech,
incorrect word use, general disinhibition, and disinhibition of
speech specifically. At follow-up, the patient reported a general
worsening of complaints.
Neuropsychological report at follow-up stated weak
performance of divided attention, and below-average language
performance, processing speed and working memory. The
other domains, among which memory and social cognition,
demonstrated average scores. In comparison with baseline
neuropsychological examination there was progression in one
attention and one processing speed task, while other scores
remained stable.
The patient did not receive a follow-upMRI due to pacemaker
placement after baseline. The radiological report of conventional
imaging at baseline stated mild global atrophy (GCA 1),
which was somewhat more pronounced in the parietal lobe.
There were some WM lesions (Fazekas 1). Importantly, as the
patient reported memory problems, the report stated that no
hippocampal atrophy was observed.
Case 5
Patient 5 was a 67-years-old male in whom behavioral changes
were first noticed 10 years previously. Major complaints included
loss of empathy, impulsive purchases, increased intake of
food, isolated behavior, unhappiness, increased anger triggered
by minor events, loss of initiative, reduced vocabulary and
forgetfulness. At follow-up, an increase in anger and decrease in
interest and empathy was reported by both patient and partner.
The neuropsychological report at follow-up stated average
and above-average performance on cognitive domains, with
the exception of weak performance on emotion recognition.
The report concluded that no cognitive disorders were
objectified, and that there were no changes in comparison with
neuropsychological examination at baseline.
The radiological report of conventional imaging at follow-
up stated no cortical atrophy or WM lesions, other than known
lacunar infarcts in the brainstem and a cortical infarct in the right
parietal lobe. This profile was not different fromMRI at baseline.
Case 6
Patient 6 was a 63-years-old male in whom behavioral changes
were first noticed 20 years previously. Major complaints
included short-term memory loss, reduced personal hygiene,
verbal aggressiveness, inappropriate—e.g., sexual–remarks,
word-finding problems, and loss of control concerning eating
-mainly sweets-, and smoking. Alcohol intake was controlled by
patient’s partner, as it would be excessive otherwise. At follow-up,
increased passive behavior was reported by the partner.
Neuropsychological report at follow-up stated disorders of
executive functioning, attention and social cognition. Weak
memory performance was observed for encoding of new
material, retaining and recall. Visuoconstruction and praxis were
abnormal. There were no evident disorders of language and
orientation. In comparison with baseline neuropsychological
examination, minimal progression was observed for executive
functioning, social cognition and processing speed. However,
overall the cognitive profile was stable in comparison with
neuropsychological examination performed in 2003, 10 years
prior to baseline study examination.
The radiological report of conventional imaging at follow-
up stated minimal frontal atrophy, which did not show evident
progression in comparison with baseline MRI. Additionally,
3 microbleeds were observed, of which a hypertensive origin
was suggested.
Qualitative Comparison of Baseline and
Follow-Up
Patients with phFTD performed worse on follow-up
neuropsychological assessment than at baseline for the
Frontiers in Neurology | www.frontiersin.org 5 November 2019 | Volume 10 | Article 1207
Meijboom et al. Longitudinal Changes in Phenocopy FTD
domains language and memory. Follow-up and baseline
scores for visuoconstructive functioning and attention and
executive functioning were comparable. Follow-up phFTD
scores for all domains (Table 4) were in between scores of
bvFTD patients and controls (Figure 1). Any differences
between individual results reported in Table 4 and clinical
neuropsychological reports are due to different assessment
strategies (i.e., calculation of domain scores vs. clinical
(individual test) interpretation).
Whole-brain, frontal and temporal GM volume (Figure 2,
Table 5) in phFTD upon follow-up were similar to baseline
and in between volumes of bvFTD and controls. Parietal and
occipital GM volume in phFTD at follow-up were also similar
to baseline measures and lower than controls, similar to bvFTD
for parietal GM, and lower than bvFTD for occipital GM.
WM tract FA in follow-up phFTD was similar to baseline
phFTD (Figure 3, Table 6), and generally in between bvFTD and
controls. However, whole-brain and lobar perfusion in follow-
up phFTD was increased in comparison with baseline phFTD
(Figure 4, Table 5).
DISCUSSION
The aim of this study was to explore brain changes in phFTD over
a 3-years time period using advanced neuroimaging techniques,
and to report these brain changes as well as cognitive changes
by means of a descriptive case series. It is of note that due to
the qualitative nature of the study, strong conclusions cannot
be drawn, but the results however can and should be used as
a motivation for further studies. We chose to highlight any
individual changes over 10%, to separate these from cases with
only minimal changes and reduce the risk of overinterpretation.
Clinically, no clear progression was observed after 3 years in
phFTD cases with disease durations ranging from 8 to 20 years.
Neuropsychological examination showed—similar to baseline—
that cognitive profiles may be normal or may be suggestive of
bvFTD, and that over time they may remain stable, or show
some progression of existing cognitive abnormalities, yet still
not fulfilling criteria for a full bvFTD profile. Conventional MRI
showed no atrophy, or only unspecific atrophy that did not
or only mildly progress. Qualitative comparison of cognitive
TABLE 4 | Cognitive domain z-scores for phenocopy frontotemporal dementia (phFTD) cases at baseline and follow-up.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Language Baseline −2.90 −8.33 −0.96 −2.12 −0.57 −1.73
Follow-up −5.62* −8.72 −1.73* −4.06* −2.12* −2.12*
Attention and executive functioning Baseline −1.80 −2.55 −0.92 −1.09 0.26 −2.28
Follow-up −1.64 −2.98* −0.68* −0.78* 0.07* −3.22*
Memory Baseline −0.88 0.35 −1.12 −0.87 −0.14 −3.01
Follow-up −1.77* −0.89* −1.60* −0.07* −0.56* −3.43*
Visuoconstructive functioning Baseline −0.54 −0.54 0.61 −0.54 −1.68 −2.83
Follow-up 0.61* −0.54 −0.54* 0.61* −1.68 −5.11*
More than 10% difference between baseline and follow-up is indicated by an asterisk.
FIGURE 1 | Mean cognitive domain z-scores for each group (baseline phFTD, follow-up phFTD, bvFTD). Z-scores are calculated using means of controls as a
reference (i.e., control mean = 0, hence not visible in the graph). The range of scores is indicated by a minimum-maximum bar. Domains assessed were language,
attention and executive functioning, memory, and visuoconstructive functioning. bvFTD, behavioral variant frontotemporal dementia; phFTD, phenocopy
frontotemporal dementia; BL, baseline; FU, follow-up.
Frontiers in Neurology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 1207
Meijboom et al. Longitudinal Changes in Phenocopy FTD
FIGURE 2 | Whole-brain and regional gray matter (GM) volume expressed as percentage of intracranial volume (ICV) shown for each group (controls, baseline phFTD,
follow-up phFTD, bvFTD). The range of scores is indicated by a minimum-maximum bar. bvFTD, behavioral variant frontotemporal dementia; phFTD, phenocopy
frontotemporal dementia; BL, baseline; FU, follow-up.
TABLE 5 | Whole brain and regional gray matter (GM) volume (% intracranial volume) and cerebral blood flow (CBF in ml/100 g gm/min) for phenocopy frontotemporal
dementia (phFTD) cases at baseline and follow-up.
Case 1 Case 2 Case 3 Case 5 Case 6
Whole-brain GM volume (%ICV) Baseline 0.3491 0.2759 0.3368 0.3165 0.3083
Follow-up 0.3433 0.2589 0.3374 0.3215 0.3408*
Frontal lobe GM Baseline 0.1220 0.0979 0.1212 0.1196 0.1193
Follow-up 0.1190 0.0919 0.1205 0.1219 0.1309
Temporal lobes GM Baseline 0.0875 0.0707 0.0792 0.0825 0.0706
Follow-up 0.0867 0.0681 0.0793 0.0838 0.0784*
Parietal lobes GM Baseline 0.0727 0.0575 0.0712 0.0573 0.0617
Follow-up 0.0707 0.0538 0.0711 0.0583 0.0690*
Occipital lobes GM Baseline 0.0466 0.0361 0.0493 0.0399 0.0410
Follow-up 0.0462 0.0321* 0.0506 0.0404 0.0440
Whole-brain CBF Baseline 37.49 59.88 28.36 42.60 42.19
Follow-up 54.45* 60.86 36.18* 44.14 50.54*
Frontal lobes CBF Baseline 39.49 68.45 35.28 49.22 46.96
Follow-up 55.86* 70.78 47.81* 44.22* 52.26*
Temporal lobes CBF Baseline 36.93 55.39 30.30 40.44 40.70
Follow-up 57.48* 60.44 34.24* 42.13 43.52
Parietal lobes CBF Baseline 37.82 55.83 28.68 39.30 42.54
Follow-up 53.20* 56.27 38.17* 41.71 56.14*
Occipital lobes CBF Baseline 35.18 51.49 17.11 47.56 38.22
Follow-up 46.49* 47.71 19.75* 48.61 46.78*
More than a 10% difference between baseline and follow-up is indicated by an asterisk.
performance at baseline and follow-up showed some progression
in the language and memory domains, yet all cognitive domain
scores were still in between those of bvFTD and controls.
Qualitative comparison of advanced MRI measures showed that
structural brain abnormalities in phFTD showed no evident
progression and were generally in between bvFTD and controls,
and that functional brain abnormalities, i.e., hyperperfusion,
progressed over time and were more pronounced than in bvFTD
and controls.
This case series study illustrates that phFTD does not show
clear longitudinal clinical changes. However, cognitive domain
scores indicated decreased scores for language and memory;
this may suggest that progression of these domains clinically
may become apparent before that of other cognitive domains,
although their scores were still in between those of bvFTD
and controls. Additionally, behavioral changes were reported
subjectively by the partner and/or patient, but these were not
evidently supported by neuropsychological testing, making their
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FIGURE 3 | White matter (WM) microstructure represented by fractional anisotropy (FA) per WM tract shown for each group (controls, baseline phFTD, follow-up
phFTD, bvFTD). The range of FA is indicated by a minimum-maximum bar. WM tracts included are the bilateral anterior thalamic radiation (ATR), bilateral cingulate
cingulum (CGC), bilateral hippocampal cingulum (CGH), forceps major (FMA), forceps minor (FMI), bilateral inferior fronto-occipital fasciculus (IFOF), bilateral inferior
longitudinal fasciculus (ILF), bilateral superior longitudinal fasciculus (SLF), and bilateral uncinate fasciculus (UF). bvFTD, behavioral variant frontotemporal dementia;
phFTD, phenocopy frontotemporal dementia; BL, baseline; FU, follow-up.
interpretation difficult. Importantly, this study also suggests
that structural abnormalities, such as GM volume and WM
microstructure, appear both to be relatively stable with measures
generally in between bvFTD and controls, whereas functional
abnormalities do indicate longitudinal changes. Higher perfusion
was observed for the whole brain and for each lobe, which is in
line with our previous findings (15). A firm conclusion cannot
be drawn, as we could not perform any formal comparisons
with controls and baseline measurements due to the small
sample. However, we can speculate on this finding, as previous
literature has hypothesized that functional changes may be
related to a mechanism compensating for subtle neuronal
dysfunctioning (41, 42). In order for the brain to maintain
performance at its normal level, despite such subtle neuronal
dysfunctioning, a higher level of perfusion is required. As
the neuronal dysfunctioning increases, this mechanism will
ultimately fail, resulting in both hypoperfusion as well as
diminished performance noticeable at a clinical level. Our
hypothesis here is that there is very mild deterioration of
neuronal functioning over time in phFTD, which is not clinically
obvious due to such a compensatory mechanism at this time.
This case series study also points out the diversity of the
phFTD clinical profile and the difficulties with diagnosis. For
instance, a long disease duration, behavioral profiles, cognitive
profiles and conventional MRI were similar amongst all cases,
but were not the same. A specific example is case 2 who,
in comparison with other cases, showed lower GM volumes,
lower neuropsychological scores, higher perfusion and lower FA.
Together with mild clinical progression, we could speculate that
this patient is in a slightly more advanced disease stage than the
other cases. However, disease duration is 12 years, which is still
very much unlike bvFTD. This emphasizes the need for long-
term follow-up, with repeated assessments to understand disease
development in this particular case, and in phFTD in general.
As bvFTD and phFTD patients were originally included in
different research studies, bvFTD patients and part of the control
group were scanned on a different scanner. This may have
induced slight variation in acquisition, such as in label efficiency
in the ASL scans. However, although a scanner effect cannot
be excluded entirely, a possible bias is expected to be minimal,
as the scanners were of the same type and field strength, and
scans were acquired with identical scan protocols. Importantly,
the longitudinal measurements in phFTD were all acquired
on the same scanner. Additionally, 3-years follow-up data for
bvFTD patients and controls were not available for the present
study, which may mean that possible changes due to aging
have not been accounted for (43). Of note is that the structural
measures in phFTD remained stable over time. Also, perfusion
has been found to decrease with age rather than increase (44–47),
suggesting the observed higher perfusion in the current study is
unrelated to an age effect. Additionally with respect to cognition,
the observed change in memory is small and it is difficult to be
certain this is unrelated to aging, however, given the extent of
change in the language domain, it is expected that this is not due
to aging alone.
A remarkable finding was an increase of GM volume in
case 6 (10.5% overall GM, 11.05% temporal GM, 11.8% parietal
GM). Because this was not observed in the other cases, caution
with interpretation is still warranted. The literature around GM
volume increase is not straightforward, but there are studies
Frontiers in Neurology | www.frontiersin.org 8 November 2019 | Volume 10 | Article 1207
Meijboom et al. Longitudinal Changes in Phenocopy FTD
TABLE 6 | White matter (WM) tract fractional anisotropy for phenocopy frontotemporal dementia (phFTD) cases at baseline and follow-up.
Case 1 Case 2 Case 3 Case 5 Case 6
Anterior thalamic radiation L Baseline 0.35 0.32 0.37 0.35 0.36
Follow-up 0.34 0.30 0.36 0.34 0.30*
Anterior thalamic radiation R Baseline 0.33 0.35 0.38 0.33 0.34
Follow-up 0.32 0.32 0.37 0.34 0.33
Cingulate cingulum L Baseline 0.51 0.45 0.48 0.41 0.50
Follow-up 0.52 0.45 0.54* 0.42 0.52
Cingulate cingulum R Baseline 0.44 0.38 0.51 0.38 0.50
Follow-up 0.46 0.39 0.50 0.38 0.43*
Hippocampal cingulum L Baseline 0.42 0.35 0.35 0.36 0.38
Follow-up 0.43 0.31* 0.38 0.39 0.40
Hippocampal cingulum R Baseline 0.43 0.36 0.40 0.40 0.42
Follow-up 0.40 0.38 0.40 0.43 0.37*
Forceps major Baseline 0.57 0.45 0.64 0.50 0.46
Follow-up 0.52 0.44 0.64 0.50 0.49
Forceps minor Baseline 0.67 0.51 0.64 0.55 0.51
Follow-up 0.66 0.48 0.68 0.56 0.52
Inferior fronto-occipital fasciculus L Baseline 0.45 0.41 0.53 0.46 0.43
Follow-up 0.46 0.39 0.46* 0.48 0.40
Inferior fronto-occipital fasciculus R Baseline 0.47 0.42 0.47 0.50 0.42
Follow-up 0.48 0.41 0.49 0.52 0.45
Inferior longitudinal fasciculus L Baseline 0.45 0.36 0.49 0.41 0.41
Follow-up 0.44 0.36 0.47 0.42 0.40
Inferior longitudinal fasciculus R Baseline 0.47 0.37 0.50 0.41 0.41
Follow-up 0.44 0.38 0.51 0.43 0.40
Superior longitudinal fasciculus L Baseline 0.40 0.31 0.42 0.37 0.37
Follow-up 0.39 0.32 0.42 0.38 0.37
Superior longitudinal fasciculus R Baseline 0.39 0.32 0.43 0.32 0.36
Follow-up 0.39 0.32 0.42 0.32 0.35
Uncinate fasciculus L Baseline 0.46 0.39 0.49 0.40 0.38
Follow-up 0.42 0.39 0.48 0.37 0.39
Uncinate fasciculus R Baseline 0.43 0.35 0.42 0.38 0.36
Follow-up 0.40 0.35 0.43 0.39 0.41*
More than a 10% difference between baseline and follow-up is indicated by an asterisk. L, left; R, right.
showing GM volume increases after, for example, mind-body
or cognitive exercises (48, 49). However, we do not know if the
patient carried out such exercises; it was not the aim of the study
to assess this.
Our study is qualitative in nature due to the small sample
size inherent to rare diseases. This limits us in the amount
of detail we can apply to the MR analyses performed and
prevents us from applying formal testing. We acknowledge that
possibly relevant brain changes remain obscured due to reporting
MR findings on a whole-brain and lobar level. However, by
doing so, we minimize the risk of over interpretation. Future
studies with a higher phFTD sample size are encouraged to
investigate structural and functional changes at a more detailed
region-of-interest level. Despite the lack of formal statistical
testing, we feel that our observations still provide important
information: phFTD is a rare and still mostly unexplained
syndrome, so any additional information is of great value
for further understanding and diagnosis. A few studies—
to our knowledge—have investigated longitudinal changes in
phFTD. In summary, these studies observed a benign disease
course over 3-years follow-up in bvFTD patients without—or
borderline—conventional MRI abnormalities at presentation (7);
did not observe a reported decline of daily living activities
over 12 months in patients with bvFTD symptomatology and
without conventional MRI abnormalities (6), found no reported
progression in clinical records of a subset of bvFTD patients
(8); did not observe progression on conventional MRI and
neuropsychological testing over a long follow-up (13–21 years)
in cases with bvFTD symptomatology and without original
clinical progression over 3-years (50); did not observe a clear
pattern of FTD pathology post-mortem in two cases with
bvFTD symptomatology and without clinical progression (51);
and found very slow progression of symptoms over 20 years
in one patient with post-mortem confirmed early-stage FTD
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FIGURE 4 | Whole-brain perfusion and lobar perfusion shown for each group (controls, baseline phFTD, follow-up phFTD, bvFTD). The range of perfusion is indicated
by a minimum-maximum bar. CBF, cerebral blood flow; bvFTD, behavioral variant frontotemporal dementia; phFTD, phenocopy frontotemporal dementia;
BL, baseline; FU, follow-up.
and a similar very slow progression rate over 15 years in this
patient’s son (52). Our study adds to the still limited knowledge
of longitudinal changes in phFTD.
In conclusion, phFTD patients extensively assessed at 3-
years follow-up show symptomatology similar to bvFTD, but
with a relatively stable clinical profile. They showed functional
brain changes, stable structural brain abnormalities, and some
cognitive deficit progression, with cognition and structure
generally in between normal and bvFTD. Overall, we suggest
that these observations are in line with the notion that
phFTD and bvFTD may belong to the same disease spectrum.
Despite the fact that a descriptive case series does not allow
for strong conclusions, we may use these observations as
motivation and a basis for further longitudinal studies in
phFTD, specifically exploring the structural vs. functional brain
changes. Future longitudinal studies of phFTD are a necessity for
improved insight, accurate diagnosis and appropriate treatment
in these patients.
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